Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
Level 3 - non-randomized controlled study
Post-hoc exploratory analysis of three previously conducted clinical trials
PubMed 27418543 · doi:10.1016/j.prostaglandins.2016.07.007
What was done
A post-hoc exploratory analysis evaluated the relationship between icosapent ethyl dose and eicosapentaenoic acid (EPA) concentrations in plasma and red blood cells (RBCs) across three clinical studies: a Phase 1 pharmacokinetic study in healthy adult volunteers and two Phase 3 randomized trials (MARINE and ANCHOR) in adults with hypertriglyceridemia. The analysis also evaluated the correlation between achieved EPA levels and triglyceride (TG) lowering in MARINE and ANCHOR.
What was found
Icosapent ethyl produced dose-dependent increases in plasma and RBC EPA concentrations across all three studies. Increases in EPA concentrations significantly correlated with the degree of TG lowering in both MARINE and ANCHOR (all P < 0.01). In patients with baseline TG levels >= 200 mg/dL treated with icosapent ethyl 4 g/day, end-of-treatment concentrations were > 170 ug/mL for plasma EPA and > 70 ug/mL for RBC EPA.
Why it matters
These findings show that icosapent ethyl exhibits predictable pharmacokinetics and that its triglyceride-lowering efficacy directly tracks circulating and cellular EPA exposure.
Limits
The abstract does not report total sample size, baseline demographic characteristics, correlation coefficients, or exact percentage reductions in triglycerides. As a post-hoc exploratory analysis, the findings are hypothesis-generating rather than prespecified primary endpoints.
Cited by
- supports The standard prescription dose of omega-3 fatty acids for patients with hypertriglyceridemia or cardiovascular disease is 4 grams per day.